{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:39:09Z","timestamp":1784885949205,"version":"3.55.0"},"reference-count":159,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["egastro"],"accepted":{"date-parts":[[2023,9,15]]},"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>The current mainstay treatment modalities for inflammatory bowel disease (IBD) include immunomodulators (methotrexate and thiopurines), biologics (antitumour necrosis factor alpha (TNF-\u03b1) being the most commonly used) and other monoclonal antibodies such as the anti-integrins and anti-interleukins (IL-12\/23). While ideally treatment should be initiated early in the disease process to avoid relapses and complications, the major recurring issue continues to be primary and secondary loss of response, with often \u2018diminishing returns\u2019 in terms of efficacy for the next line of therapies prescribed for patients with IBD. Additional concerns include the long-term risk factors such as malignancy and susceptibility to infections. Recently, there has been an influx of new and emerging medications entering the market that are showing promising efficacy results in patients with moderate-to-severe disease who have previously failed to respond to multiple drugs. This review will focus on these novel and emerging therapies\u2014in essence, \u2018horizon scanning\u2019\u2014which includes the antiadhesion agents, cytokine inhibitors, Janus kinase inhibitors, phosphodiesterase inhibitors, sphingosine-1 phosphate receptor modulators and MicroRNA-124 (miR-124) upregulators.<\/jats:p>","DOI":"10.1136\/egastro-2023-100012","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T13:25:24Z","timestamp":1698413124000},"page":"e100012","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":34,"title":["Horizon scanning: new and future therapies in the management of inflammatory bowel disease"],"prefix":"10.1136","volume":"1","clinical-trial-number":[{"clinical-trial-number":"nct03290781","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03566823","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04857112","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05507203","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05507216","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05535946","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05242484","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05242471","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02764762","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Aditi","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1568-3978","authenticated-orcid":false,"given":"Philip J","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"2024122507500854000_1.2.e100012.1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab228"},{"key":"2024122507500854000_1.2.e100012.2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.233"},{"key":"2024122507500854000_1.2.e100012.3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"2024122507500854000_1.2.e100012.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.186"},{"key":"2024122507500854000_1.2.e100012.5","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/ibd\/izz059","article-title":"The role of early biologic therapy in inflammatory bowel disease","volume":"25","author":"Berg","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2024122507500854000_1.2.e100012.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.06.002"},{"key":"2024122507500854000_1.2.e100012.7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18091973","article-title":"Can we predict the efficacy of anti-TNF-alpha agents","volume":"18","author":"Lopetuso","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2024122507500854000_1.2.e100012.8","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10225318","article-title":"Primary failure to an anti-TNF agent in inflammatory bowel disease: switch (to a second anti-TNF agent) or swap (for another mechanism of action)?","volume":"10","author":"Gisbert","year":"2021","journal-title":"J Clin Med"},{"key":"2024122507500854000_1.2.e100012.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804"},{"key":"2024122507500854000_1.2.e100012.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"2024122507500854000_1.2.e100012.11","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3748\/wjg.v26.i14.1554","article-title":"Optimized timing of using Infliximab in perianal fistulizing Crohn\u2019s disease","volume":"26","author":"Sun","year":"2020","journal-title":"World J Gastroenterol"},{"key":"2024122507500854000_1.2.e100012.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"2024122507500854000_1.2.e100012.13","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(18)32196-2","article-title":"Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn\u2019s disease: an international, randomised, double-blind, phase 3 non-inferiority study","volume":"393","author":"Ye","year":"2019","journal-title":"Lancet"},{"key":"2024122507500854000_1.2.e100012.14","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous Infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"2024122507500854000_1.2.e100012.15","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of switching from intravenous to subcutaneous Infliximab in patients with inflammatory bowel diseases: the REMSWITCH study","volume":"21","author":"Buisson","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024122507500854000_1.2.e100012.16","doi-asserted-by":"crossref","first-page":"i161","DOI":"10.1093\/ecco-jcc\/jjac190.0126","article-title":"Dop86 subcutaneous Infliximab (CT-P13 SC) as maintenance therapy for Crohn\u2019s disease: a phase 3, randomised, placebo-controlled study (LIBERTY-CD)","volume":"17","author":"Colombel","year":"2023","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2024122507500854000_1.2.e100012.17","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","article-title":"Efficacy and safety of elective switching from intravenous to subcutaneous Infliximab [CT-P13]: a multicentre cohort study","volume":"16","author":"Smith","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2024122507500854000_1.2.e100012.18","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/ibd.21888","article-title":"Systematic assessment of factors influencing preferences of Crohn\u2019s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL)","volume":"18","author":"Vavricka","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2024122507500854000_1.2.e100012.19","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s11845-018-1925-8","article-title":"The non-drug costs associated with the administration of an intravenous biologic treatment in the hospital setting","volume":"188","author":"Cronin","year":"2019","journal-title":"Ir J Med Sci"},{"key":"2024122507500854000_1.2.e100012.20","doi-asserted-by":"publisher","DOI":"10.1159\/000320413"},{"key":"2024122507500854000_1.2.e100012.21","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e3182a11958"},{"key":"2024122507500854000_1.2.e100012.22","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw036"},{"key":"2024122507500854000_1.2.e100012.23","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw026"},{"key":"2024122507500854000_1.2.e100012.24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/MCG.0000000000001314","article-title":"Novel orally administered recombinant anti-TNF alpha fusion protein for the treatment of ulcerative colitis: results from a phase 2A clinical trial","volume":"55","author":"Almon","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"2024122507500854000_1.2.e100012.25","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.imbio.2016.11.001","article-title":"A plant cell-expressed recombinant anti-TNF fusion protein is biologically active in the gut and alleviates immune-mediated hepatitis and colitis","volume":"222","author":"Ilan","year":"2017","journal-title":"Immunobiology"},{"key":"2024122507500854000_1.2.e100012.26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jim.2017.03.023","article-title":"An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy","volume":"446","author":"Almon","year":"2017","journal-title":"J Immunol Methods"},{"key":"2024122507500854000_1.2.e100012.27","doi-asserted-by":"crossref","first-page":"i56","DOI":"10.1093\/ecco-jcc\/jjac190.0040","article-title":"OP40 PRA023 demonstrated efficacy and favorable safety as induction therapy for moderately to severely active UC: phase 2 ARTEMIS-UC study results","volume":"17","author":"Sands","year":"2023","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2024122507500854000_1.2.e100012.28","doi-asserted-by":"crossref","first-page":"i162","DOI":"10.1093\/ecco-jcc\/jjac190.0127","article-title":"Dop87 the anti-Tl1A antibody PRA023 demonstrated proof-of-concept in Crohn\u2019s disease: phase 2A APOLLO-CD study results","volume":"17","author":"Feagan","year":"2023","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2024122507500854000_1.2.e100012.29","first-page":"265","article-title":"Sphingosine-1 phosphate receptor Modulators: the next wave of oral therapies in inflammatory bowel disease","volume":"18","author":"Choden","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2024122507500854000_1.2.e100012.30","doi-asserted-by":"publisher","DOI":"10.2174\/156652409789105525"},{"key":"2024122507500854000_1.2.e100012.31","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.2174\/13894501113149990158","article-title":"Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease","volume":"14","author":"Bamias","year":"2013","journal-title":"Curr Drug Targets"},{"key":"2024122507500854000_1.2.e100012.32","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin","year":"1997","journal-title":"Am J Pathol"},{"key":"2024122507500854000_1.2.e100012.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"2024122507500854000_1.2.e100012.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739"},{"key":"2024122507500854000_1.2.e100012.35","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2024122507500854000_1.2.e100012.36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn\u2019s disease: results from the VISIBLE 2 randomised trial","volume":"16","author":"Vermeire","year":"2022","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2024122507500854000_1.2.e100012.37","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/apt.16927","article-title":"Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease","volume":"55","author":"Bergqvist","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2024122507500854000_1.2.e100012.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60661-9"},{"key":"2024122507500854000_1.2.e100012.39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(21)00338-1","article-title":"Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials","volume":"7","author":"Rubin","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024122507500854000_1.2.e100012.40","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2468-1253(21)00298-3","article-title":"Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial","volume":"7","author":"Peyrin-Biroulet","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024122507500854000_1.2.e100012.41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S2468-1253(21)00295-8","article-title":"Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study","volume":"7","author":"Vermeire","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024122507500854000_1.2.e100012.42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S2468-1253(21)00294-6","article-title":"Etrolizumab versus Infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study","volume":"7","author":"Danese","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024122507500854000_1.2.e100012.43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2468-1253(22)00303-X","article-title":"Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial","volume":"8","author":"Sandborn","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024122507500854000_1.2.e100012.44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00137.x"},{"key":"2024122507500854000_1.2.e100012.45","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/ecco-jcc\/jjab023","article-title":"Long-term safety and efficacy of the anti-Madcam-1 monoclonal antibody ontamalimab [SHP647] for the treatment of ulcerative colitis: the open-label study TURANDOT II","volume":"15","author":"Reinisch","year":"2021","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2024122507500854000_1.2.e100012.46","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/ibd\/izab215","article-title":"Long-term safety and efficacy of the anti-mucosal addressin cell adhesion molecule-1 monoclonal antibody ontamalimab (SHP647) for the treatment of Crohn\u2019s disease: the OPERA II study","volume":"28","author":"D\u2019Haens","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2024122507500854000_1.2.e100012.47","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11030747","article-title":"Exploring the pipeline of novel therapies for inflammatory bowel disease","volume":"11","author":"Zurba","year":"2023","journal-title":"Biomedicines"},{"key":"2024122507500854000_1.2.e100012.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.06.008"},{"key":"2024122507500854000_1.2.e100012.49","first-page":"255","article-title":"The expanding role of anti-IL-12 and\/or anti-IL-23 antibodies in the treatment of inflammatory bowel disease","volume":"15","author":"Kashani","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2024122507500854000_1.2.e100012.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203572"},{"key":"2024122507500854000_1.2.e100012.51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207940"},{"key":"2024122507500854000_1.2.e100012.52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5639\/gabij.2019.0801.003","article-title":"Patent expiry dates for BIOLOGICALS: 2018 update","volume":"8","year":"2019","journal-title":"GaBI J"},{"key":"2024122507500854000_1.2.e100012.53","unstructured":"Mehr S . Ustekinumab Biosimilars update. Biosimilars review and report. 2021."},{"key":"2024122507500854000_1.2.e100012.54","unstructured":"Taylor NP . Celltrion signs up to support Rani\u2019s oral biosimilar copy of J&J\u2019s Stelara, lands right of first negotiation. Fierce Pharma, 2023."},{"key":"2024122507500854000_1.2.e100012.55","unstructured":"Technology Appraisal Guidance (TA888) . Risankizumab for previously treated moderately to severely active Crohn\u2019s disease. 2023."},{"key":"2024122507500854000_1.2.e100012.56","unstructured":"Abbvie . SKYRIZI\u00ae (Risankizumab-Rzaa) receives FDA approval as the first and only specific Interleukin-23 (IL-23) to treat moderately to severely active Crohn\u2019s disease in adults. n.d. Available: https:\/\/news.abbvie.com\/news\/press-releases\/skyrizi-risankizumab-rzaa-receives-fda-approval-as-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults.htm"},{"key":"2024122507500854000_1.2.e100012.57","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00467-6"},{"key":"2024122507500854000_1.2.e100012.58","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"2024122507500854000_1.2.e100012.59","unstructured":"Jenina Nun LS . Risankizumab (SKYRIZI\u00ae) achieves primary and all secondary endpoints in phase 3 induction study in patients with ulcerative colitis. Abbvie. Available: https:\/\/news.abbvie.com\/news\/press-releases\/risankizumab-skyrizi-achieves-primary-and-all-secondary-endpoints-in-phase-3-induction-study-in-patients-with-ulcerative-colitis.htm#:~:text=%22These%20results%20suggest%20that%20risankizumab,bowel%20urgency%20and%20fecal%20incontinence.%22&text=Primary%20endpoint%20was%20clinical%20remission%20(per%20Adapted%20Mayo%20Score) [Accessed 23 Mar 2023]."},{"key":"2024122507500854000_1.2.e100012.60","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2024122507500854000_1.2.e100012.61","first-page":"3","article-title":"Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 LUCENT-2 study","volume":"18","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2024122507500854000_1.2.e100012.62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207940"},{"key":"2024122507500854000_1.2.e100012.63","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.10.050"},{"key":"2024122507500854000_1.2.e100012.64","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of Crohn\u2019s disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"2024122507500854000_1.2.e100012.65","unstructured":"AJe . The efficacy and safety of Guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 QUASAR induction study. Presented at: Digestive Disease Week; Chicago, 2023"},{"key":"2024122507500854000_1.2.e100012.66","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024122507500854000_1.2.e100012.67","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.03.049"},{"key":"2024122507500854000_1.2.e100012.68","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i48.8242"},{"key":"2024122507500854000_1.2.e100012.69","unstructured":"AztraZeneca . Update on Brazikumab development programme. n.d. Available: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/update-on-brazikumab-development-programme.html"},{"key":"2024122507500854000_1.2.e100012.70","doi-asserted-by":"crossref","first-page":"ii45","DOI":"10.1093\/rheumatology\/keaa896","article-title":"Jak1 inhibition and inflammatory bowel disease","volume":"60","author":"Harris","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024122507500854000_1.2.e100012.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2013.06.007"},{"key":"2024122507500854000_1.2.e100012.72","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1532291"},{"key":"2024122507500854000_1.2.e100012.73","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.01.029"},{"key":"2024122507500854000_1.2.e100012.74","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312735"},{"key":"2024122507500854000_1.2.e100012.75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910"},{"key":"2024122507500854000_1.2.e100012.76","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/apt.15555","article-title":"Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE open","volume":"51","author":"Sands","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2024122507500854000_1.2.e100012.77","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cgh.2021.02.043","article-title":"Efficacy and safety of tofacitinib in ulcerative colitis based on prior tumor necrosis factor inhibitor failure status","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"2024122507500854000_1.2.e100012.78","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-05492-y"},{"key":"2024122507500854000_1.2.e100012.79","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","article-title":"Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study","volume":"19","author":"Berinstein","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024122507500854000_1.2.e100012.80","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15514"},{"key":"2024122507500854000_1.2.e100012.81","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40265-020-01346-4","article-title":"Safety of new biologics (Vedolizumab and Ustekinumab) and small molecules (tofacitinib) during pregnancy: a review","volume":"80","author":"Gisbert","year":"2020","journal-title":"Drugs"},{"key":"2024122507500854000_1.2.e100012.82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjac115","article-title":"European Crohn\u2019s and colitis guidelines on sexuality, fertility, pregnancy, and Lactation","volume":"17","author":"Torres","year":"2023","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2024122507500854000_1.2.e100012.83","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/ibd\/izab037","article-title":"The role of new oral treatment in inflammatory bowel disease","volume":"27","author":"Garrido","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2024122507500854000_1.2.e100012.84","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2B\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"2024122507500854000_1.2.e100012.85","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"2024122507500854000_1.2.e100012.86","doi-asserted-by":"crossref","first-page":"i019","DOI":"10.1093\/ecco-jcc\/jjab232.017","article-title":"Op18 efficacy and safety of Filgotinib for the treatment of perianal fistulizing Crohn\u2019s disease: results from the phase 2 divergence 2 study","volume":"16","author":"Reinisch","year":"2022","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2024122507500854000_1.2.e100012.87","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1007\/s12325-022-02168-4","article-title":"MANTA and MANTA-ray: rationale and design of trials evaluating effects of filgotinib on semen parameters in patients with inflammatory diseases","volume":"39","author":"Hellstrom","year":"2022","journal-title":"Adv Ther"},{"key":"2024122507500854000_1.2.e100012.88","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00581-5"},{"key":"2024122507500854000_1.2.e100012.89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212728"},{"key":"2024122507500854000_1.2.e100012.90","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.12998\/wjcc.v11.i8.1730","article-title":"Pregnancy and medications for inflammatory bowel disease: an updated narrative review","volume":"11","author":"Akiyama","year":"2023","journal-title":"World J Clin Cases"},{"key":"2024122507500854000_1.2.e100012.91","doi-asserted-by":"crossref","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u039aB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct Target Ther"},{"key":"2024122507500854000_1.2.e100012.92","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.01.001"},{"key":"2024122507500854000_1.2.e100012.93","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00508.2007"},{"key":"2024122507500854000_1.2.e100012.94","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2009.03.001"},{"key":"2024122507500854000_1.2.e100012.95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"2024122507500854000_1.2.e100012.96","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1016\/j.cgh.2019.12.032","article-title":"Effects of Apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis","volume":"18","author":"Danese","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024122507500854000_1.2.e100012.97","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaad.2020.01.072","article-title":"Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results of a phase 3B, multicenter, randomized, placebo-controlled, double-blind study","volume":"83","author":"Van Voorhees","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024122507500854000_1.2.e100012.98","doi-asserted-by":"crossref","DOI":"10.12703\/P6-109","article-title":"S1P signaling: new therapies and opportunities","volume":"6","author":"Gonzalez-Cabrera","year":"2014","journal-title":"F1000Prime Rep"},{"key":"2024122507500854000_1.2.e100012.99","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease","volume":"16","author":"Peyrin-Biroulet","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2024122507500854000_1.2.e100012.100","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R046300"},{"key":"2024122507500854000_1.2.e100012.101","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00476.x"},{"key":"2024122507500854000_1.2.e100012.102","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.gastrohep.2020.07.020","article-title":"Fingolimod-induced remission in a patient with ulcerative colitis and multiple sclerosis","volume":"44","author":"Ladr\u00f3n Abia","year":"2021","journal-title":"Gastroenterol Hepatol"},{"key":"2024122507500854000_1.2.e100012.103","doi-asserted-by":"crossref","first-page":"S678","DOI":"10.1093\/ecco-jcc\/jjx107","article-title":"Targeting S1P in inflammatory bowel disease: new avenues for modulating intestinal leukocyte migration","volume":"12","author":"Danese","year":"2018","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2024122507500854000_1.2.e100012.104","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70049-3"},{"key":"2024122507500854000_1.2.e100012.105","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"2024122507500854000_1.2.e100012.106","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01319-7"},{"key":"2024122507500854000_1.2.e100012.107","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"2024122507500854000_1.2.e100012.108","doi-asserted-by":"crossref","unstructured":"Danese S , Colombel JF , Ponich T , et al . Dop44 long-term use of ozanimod in patients with moderately to severely active ulcerative colitis. European Crohns and Colitis Organisation; Copenhagen, Denmark, 2023","DOI":"10.1093\/ecco-jcc\/jjab232.083"},{"key":"2024122507500854000_1.2.e100012.109","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","article-title":"Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded Endpoint study","volume":"5","author":"Feagan","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024122507500854000_1.2.e100012.110","doi-asserted-by":"crossref","first-page":"106958","DOI":"10.1016\/j.cct.2022.106958","article-title":"Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: the YELLOWSTONE clinical trial program","volume":"122","author":"Feagan","year":"2022","journal-title":"Contemp Clin Trials"},{"key":"2024122507500854000_1.2.e100012.111","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2147\/TCRM.S336139","article-title":"A literature review of ozanimod therapy in inflammatory bowel disease: from concept to practical application","volume":"18","author":"Becher","year":"2022","journal-title":"Ther Clin Risk Manag"},{"key":"2024122507500854000_1.2.e100012.112","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2024122507500854000_1.2.e100012.113","first-page":"S60","article-title":"P-179 safety, pharmacokinetics and pharmacodynamics of Etrasimod (Apd334), an oral selective S1P receptor modulator, after dose-escalation, in healthy volunteers","volume":"23","author":"Peyrin-Biroulet","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2024122507500854000_1.2.e100012.114","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(21)01844-8"},{"key":"2024122507500854000_1.2.e100012.115","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","article-title":"Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study","volume":"15","author":"Vermeire","year":"2021","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2024122507500854000_1.2.e100012.116","doi-asserted-by":"crossref","first-page":"i764","DOI":"10.1093\/ecco-jcc\/jjac190.0762","article-title":"P632 Etrasimod induction therapy in moderately to severely active Crohn\u2019s disease: results from a phase 2, randomised, double-blind Substudy","volume":"17","author":"D\u2019Haens","year":"2023","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2024122507500854000_1.2.e100012.117","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/ecco-jcc\/jjab201","article-title":"Placebo-controlled study to evaluate safety, tolerability, and efficacy of amiselimod in patients with moderate to severe active Crohn\u2019s disease","volume":"16","author":"D\u2019Haens","year":"2022","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2024122507500854000_1.2.e100012.118","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.07.001"},{"key":"2024122507500854000_1.2.e100012.119","first-page":"714","article-title":"The role of MicroRNA in inflammatory bowel disease","volume":"6","author":"Dalal","year":"2010","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2024122507500854000_1.2.e100012.120","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.5110"},{"key":"2024122507500854000_1.2.e100012.121","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200502000-00001"},{"key":"2024122507500854000_1.2.e100012.122","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:28:3:187"},{"key":"2024122507500854000_1.2.e100012.123","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S2468-1253(22)00233-3","article-title":"Abx464 (Obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2B, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension","volume":"7","author":"Vermeire","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024122507500854000_1.2.e100012.124","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904492"},{"key":"2024122507500854000_1.2.e100012.125","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, Multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024122507500854000_1.2.e100012.126","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024122507500854000_1.2.e100012.127","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11041076","article-title":"Selecting the best combined biological therapy for refractory inflammatory bowel disease patients","volume":"11","author":"Mas","year":"2022","journal-title":"J Clin Med"},{"key":"2024122507500854000_1.2.e100012.128","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20014"},{"key":"2024122507500854000_1.2.e100012.129","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-018-1480-0"},{"key":"2024122507500854000_1.2.e100012.130","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in Crohn's disease: the IM-UNITI trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024122507500854000_1.2.e100012.131","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-329948"},{"key":"2024122507500854000_1.2.e100012.132","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.001"},{"key":"2024122507500854000_1.2.e100012.133","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.20046"},{"key":"2024122507500854000_1.2.e100012.134","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30182-4"},{"key":"2024122507500854000_1.2.e100012.135","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10151-020-02395-3","article-title":"Fecal microbiota transplantation for Crohn\u2019s disease: a systematic review and meta-analysis","volume":"25","author":"Cheng","year":"2021","journal-title":"Tech Coloproctol"},{"key":"2024122507500854000_1.2.e100012.136","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv203"},{"key":"2024122507500854000_1.2.e100012.137","doi-asserted-by":"crossref","DOI":"10.1186\/s40168-020-0792-5","article-title":"Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study","volume":"8","author":"Sokol","year":"2020","journal-title":"Microbiome"},{"key":"2024122507500854000_1.2.e100012.138","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1164"},{"key":"2024122507500854000_1.2.e100012.139","doi-asserted-by":"crossref","first-page":"S382","DOI":"10.1093\/ecco-jcc\/jjz203.549","article-title":"P420 A randomised, observer-blinded phase IB multiple, ascending dose study of UTTR1147A, an IL-22Fc fusion protein, in healthy volunteers and ulcerative colitis patients","volume":"14","author":"Wagner","year":"2020","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2024122507500854000_1.2.e100012.140","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.651415","article-title":"Novel and emerging therapies for inflammatory bowel disease","volume":"12","author":"Al-Bawardy","year":"2021","journal-title":"Front Pharmacol"},{"key":"2024122507500854000_1.2.e100012.141","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/ecco-jcc\/jjw103","article-title":"Clinical effects of a topically applied toll-like receptor 9 agonist in active moderate-to-severe ulcerative colitis","volume":"10","author":"Atreya","year":"2016","journal-title":"ECCOJC"},{"key":"2024122507500854000_1.2.e100012.142","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S2468-1253(20)30301-0","article-title":"Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2B randomised, double-blind, placebo-controlled, dose-ranging induction trial","volume":"5","author":"Atreya","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024122507500854000_1.2.e100012.143","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.02.009"},{"key":"2024122507500854000_1.2.e100012.144","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.001"},{"key":"2024122507500854000_1.2.e100012.145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.gastro.2020.07.048","article-title":"A phase 1B safety study of SER-287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis","volume":"160","author":"Henn","year":"2021","journal-title":"Gastroenterology"},{"key":"2024122507500854000_1.2.e100012.146","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14740338.2022.2103536","article-title":"Safety and tolerability of spesolimab in patients with ulcerative colitis","volume":"22","author":"Ferrante","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"2024122507500854000_1.2.e100012.147","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314562"},{"key":"2024122507500854000_1.2.e100012.148","doi-asserted-by":"crossref","unstructured":"Mrsny R , Kanwar B , Mahmood T . Treatment of ulcerative colitis with AMT-101, a novel oral interleukin-10 immunomodulatory fusion biologic that traffics across the intestinal epithelium. GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND: OXFORD UNIV PRESS, 2020: S039\u201340.","DOI":"10.1093\/ecco-jcc\/jjz203.038"},{"key":"2024122507500854000_1.2.e100012.149","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1053\/j.gastro.2015.08.044","article-title":"Safety and efficacy of AJM300, an oral antagonist of \u03914 integrin, in induction therapy for patients with active ulcerative colitis","volume":"149","author":"Yoshimura","year":"2015","journal-title":"Gastroenterology"},{"key":"2024122507500854000_1.2.e100012.150","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4252\/wjsc.v12.i10.1113","article-title":"Medical, ethical, and legal aspects of hematopoietic stem cell transplantation for Crohn\u2019s disease in Brazil","volume":"12","author":"Ruiz","year":"2020","journal-title":"World J Stem Cells"},{"key":"2024122507500854000_1.2.e100012.151","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-292391"},{"key":"2024122507500854000_1.2.e100012.152","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.16700"},{"key":"2024122507500854000_1.2.e100012.153","doi-asserted-by":"publisher","DOI":"10.1007\/DCR.0b013e3181973487"},{"key":"2024122507500854000_1.2.e100012.154","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0b013e318255364a"},{"key":"2024122507500854000_1.2.e100012.155","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-021-02533-0","article-title":"Stem cell therapy for Crohn\u2019s disease: systematic review and meta-analysis of preclinical and clinical studies","volume":"12","author":"Wang","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"2024122507500854000_1.2.e100012.156","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.2147\/JIR.S400447","article-title":"Stem cell therapy in inflammatory bowel disease: a review of achievements and challenges","volume":"16","author":"Tian","year":"2023","journal-title":"J Inflamm Res"},{"key":"2024122507500854000_1.2.e100012.157","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158494","article-title":"Stem cell-based therapies for inflammatory bowel disease","volume":"23","author":"Zhang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024122507500854000_1.2.e100012.158","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1053\/j.gastro.2022.01.033","article-title":"Ozanimod for the treatment of ulcerative colitis","volume":"162","author":"Khanna","year":"2022","journal-title":"Gastroenterology"},{"key":"2024122507500854000_1.2.e100012.159","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01648.x"}],"container-title":["eGastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/egastro-2023-100012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T03:44:53Z","timestamp":1735271093000},"score":1,"resource":{"primary":{"URL":"http:\/\/egastroenterology.bmj.com\/lookup\/doi\/10.1136\/egastro-2023-100012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":159,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,10,27]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/egastro-2023-100012"],"URL":"https:\/\/doi.org\/10.1136\/egastro-2023-100012","relation":{},"ISSN":["2766-0125","2976-7296"],"issn-type":[{"value":"2766-0125","type":"print"},{"value":"2976-7296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}